Celgene to pay US$280m to settle cancer drug fraud suit

Celgene to pay US$280m to settle cancer drug fraud suit


Celgene Corp. has agreed to pay $280 million to settle a whistleblower lawsuit alleging the pharmaceutical company committed fraud promoting a drug with a notorious history that was re-purposed to treat leprosy and another therapy for unapproved cancer treatments, federal prosecutors announced Tuesday. The agreement settled a lawsuit in Los Angeles federal court by a former Celgene saleswoman who... Celgene Corp. has agreed to pay $280 million to settle a whistleblower lawsuit alleging the pharmaceutical company committed fraud promoting a drug with a notorious history that was re-purposed to treat leprosy and another therapy for unapproved cancer treatments, federal prosecutors announced Tuesday.



from Biotech News